Investor Presentaiton
MEDI0457 Potential to Treat Head and Neck Cancer
Demonstrated in Phase 1 Trial
Cohort 1
HPV 16/18+ HNSCC undergoing
definitive surgery (n=5)
Immunotherapy is administered
before and after surgery
Surgery
> 4 months
Cohort 2
HPV 16/18+ HNSCC undergoing
definitive/adj chemoradiation
(n=20)
Immunotherapy is administered
2 months after completion of
chemoradiation
Study Treatment: MEDI0457
Follow up for
6 months post
last dose
Primary: Safety and
MEDI0457: 6 mg of VGX-3100 + 1 mg of INO-9012
In Cohort 1, if time allows, up to 2 treatments can be administrated
prior to surgery, but total 4 treatments are scheduled
tolerability of DNA based
immunotherapy
Secondary: Cellular and
humoral immune responses
Exploratory: Anti-tumor
response and progression.
free survival
28
INOVIO
POWERING DNA MEDICINESView entire presentation